September 30, 2026 — RNews

#pharmacotherapy — Wednesday, September 30, 2026 (1 items)

hot top new

← prev day next day →

2

Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial. (linkinghub.elsevier.com)

Klein KR … Meskimen ER The Lancet 2026-09-30

#diabetes #cardiovascular #safety #glp-1 #pharmacotherapy